Icatibant Accord

Icatibant, the active ingredient in Icatibant Accord, is a bradykinin B2 receptor antagonist presented as an injectable solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in adult patients. The product is authorized in the European Union and is administered by a healthcare professional.

GNH USA supplies Icatibant Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable cold‑chain logistics and regulatory support for global distribution, and ensuring product integrity.

Icatibant is used to treat conditions mediated by excessive bradykinin activity, primarily hereditary angioedema.

Acute hereditary angioedema attacks (type I): rapid reduction of subcutaneous and submucosal edema. Acute hereditary angioedema attacks (type II): alleviation of swelling and associated discomfort. Hereditary angioedema in adults (any type): control of bradykinin‑mediated vascular permeability.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain or erythema. - Local swelling or induration at the injection site. - Nausea or mild headache. - Dizziness or fatigue.

Serious or Rare Side Effects: - Severe hypersensitivity reactions, including anaphylaxis. - Acute hypotension. - Paradoxical angioedema or airway compromise. - Thrombocytopenia or other hematologic abnormalities.

When using Icatibant, certain precautions should be observed.

Pregnancy: safety not established; use only if benefit outweighs risk. Breastfeeding: unknown safety; consider potential risks. Renal impairment: monitor as drug is primarily renally excreted. Concomitant ACE inhibitors: may increase bradykinin levels; observe for enhanced edema. Hypersensitivity: discontinue immediately if severe allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that affect bradykinin pathways.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may worsen angioedema. - Angiotensin receptor blockers: similar risk of increased bradykinin activity. - Estrogen‑containing contraceptives: may raise frequency of HAE attacks.

Moderate Interactions (Monitor Closely): - NSAIDs: can exacerbate swelling in susceptible individuals. - Diuretics: may alter fluid balance and affect symptom severity. - Other B2 receptor antagonists: no additive benefit and may increase adverse event risk.